Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Most Members Dissatisfied with Pharm. Associations: JACDS
November 13, 2006
- Nihon Chouzai: Double-Digit Drop in Profits Despite 12% Rise in Sales
November 13, 2006
- SELF-MEDICATION NEWS IN BRIEF
November 13, 2006
- Council Urges Quick Development and Approval of 3 Drugs
November 13, 2006
- Social Security Benefits Rose 1.6% in FY2004
November 13, 2006
- PMDA Aims at Global Simultaneous Review of Groundbreaking Products: Mr Mori
November 13, 2006
- 488 Adverse Events, 48 Deaths Attributed to Alteplase
November 13, 2006
- FPMAJ, JPMA Call For Revision of Transfer Price Taxation System
November 13, 2006
- SURVEY 2 articles
November 13, 2006
- Coordination Essential for More Efficient Clinical Trials: JCROA Symposium
November 13, 2006
- Guerbet to Enhance Its Visibility in Japan
November 13, 2006
- 8th Annual Meeting of the Japan Osteoporosis Society
November 6, 2006
- Price Agreement Rate Was 46.8% with Med. Institutions as of July
November 6, 2006
- Recommendation Grades of Drugs to Treat Osteoporosis Included in 2006 GL
November 6, 2006
- 24 New Drugs Approved
November 6, 2006
- R&DNEWS IN BRIEF
November 6, 2006
- SEMINAR
November 6, 2006
- OPINION
November 6, 2006
- MD Devices, Diagnostics at Chuikyo
November 6, 2006
- NEW PRODUCTS
November 6, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…